NAV-240

DRUG4 trials

Sponsors

Navigator Medicines Inc., Navigator Medicines, Inc.

Conditions

HealthyHealthy VolunteersHidradenitis Suppurativa (HS)Moderate-to-Severe Hidradenitis Suppurativa

Phase 1

Study of NAV-240 in Healthy Volunteers

CompletedNCT06181786

Navigator Medicines, Inc.Healthy

Start: 2023-11-22End: 2024-09-04Updated: 2025-06-17

A Study on the Safety, Tolerability, Bioavailability and Mechanism of Action of Intravenous NAV-240 in Adults.

CompletedNCT06933043

Navigator Medicines, Inc.Healthy Volunteers

Start: 2025-05-20End: 2025-11-20Updated: 2026-03-06

Phase 2

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

RecruitingNCT07384975

Navigator Medicines, Inc.Hidradenitis Suppurativa (HS)

Start: 2026-01-05End: 2027-10-01Target: 150Updated: 2026-02-03

A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study of NAV-240 in Adult Participants with Moderate-to-Severe Hidradenitis Suppurativa

Not yet recruitingCTIS2025-523557-33-00

Navigator Medicines Inc.Moderate-to-Severe Hidradenitis Suppurativa

Target: 80Updated: 2026-03-26